Bank of America’s Aptevo Therapeutics APVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-7
Closed -$66 5755
2025
Q4
$66 Buy
7
+5
+250% +$119 ﹤0.01% 6908
2025
Q3
$39 Buy
+2
New +$80 ﹤0.01% 8065
2025
Q2
Sell
-6
Closed -$1.09K 8299
2025
Q1
$2.69K Buy
+6
New +$7.59K ﹤0.01% 7295
2024
Q4
Hold
0
8046
2024
Q3
Hold
0
8008
2024
Q2
Hold
0
7838
2024
Q1
Hold
0
-$1 7715
2023
Q4
Hold
0
7933
2023
Q3
Hold
0
7709
2023
Q2
Hold
0
7567
2023
Q1
Hold
0
7610
2022
Q4
Hold
0
7924
2022
Q3
Hold
0
7331
2022
Q2
Hold
0
7987
2022
Q1
Hold
0
8234
2021
Q4
Hold
0
8191
2021
Q3
Hold
0
8084
2021
Q2
Hold
0
7728
2021
Q1
Hold
0
6599
2020
Q4
Hold
0
5628
2020
Q3
Hold
0
6870
2020
Q2
Hold
0
6812
2020
Q1
Hold
0
6822
2019
Q4
Hold
0
7055
2019
Q3
Hold
0
6735
2019
Q2
Hold
0
7009
2018
Q3
Hold
0
-$2K 7246
2018
Q2
Hold
0
6903
2018
Q1
Hold
0
-$1K 7082
2017
Q4
Hold
0
6903
2017
Q3
Hold
0
5991
2017
Q2
Hold
0
5863
2017
Q1
Hold
0
5918
2016
Q4
Hold
0
5890

Other funds holding APVO

Bank of America's APVO Position: Q1 2026 in Review

Bank of America sold out of Aptevo Therapeutics (APVO) in Q1 2026, closing a stake of 7 shares — an estimated $66 sold.

Bank of America first reported a position in APVO in Q1 2025 and held it in 3 quarters. The position peaked at $2.69K in Q1 2025. 9 funds tracked by Wall St. Rank hold APVO as of Q1 2026.

  • Bank of America reported no remaining Aptevo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 7 Aptevo Therapeutics shares in Q1 2026, an estimated $66.
  • Bank of America first reported a position in Aptevo Therapeutics in Q1 2025 and held it in 3 quarters.
  • Bank of America's Aptevo Therapeutics position peaked at $2.69K in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.